Familial Systemic Scleroderma

Recruiting now

Conditions studied: Systemic Scleroderma

In brief

Studying familial forms of systemic scleroderma offers several advantages: 1. To better understand the pathophysiology of a complex autoimmune disease based on "extreme" cases (familial forms); 2. To identify potential molecular markers predictive of disease progression; 3. To identify potential pathophysiological targets for developing new therapies, particularly relevant in severe and refractory forms of the disease.

Key facts

Study ID

NCT07343115

Run by

University Hospital, Strasbourg, France

People needed

20

Starts

2025-09-02

Expected to finish

2026-09-02

Last updated by the study team

2026-01-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult subjects (≥ 18 years of age)
• Subjects diagnosed with systemic scleroderma by a clinician (including limited, diffuse, and sine scleroderma SSc, as well as overlap syndromes with myositis) and meeting at least the VEDOSS criteria: Raynaud's phenomenon + 1 other criterion from among: sausage fingers, antinuclear antibodies, scleroderma-specific antibodies (anti-centromere, anti-RNApolIII, anti-ScL70), capillaroscopic abnormalities
• At least one first-degree relative with systemic scleroderma meeting the same criteria

You may not qualify if…

• Subject who has expressed opposition to participating in the study

Where it is running

• Service de Médecine interne et Immunologie clinique - CHU de Strasbourg - France — Strasbourg, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.